This page contains a Flash digital edition of a book.
Available treatments: PAH


Available treatments in PAH


The main goals of PAH treatment are to alleviate symptoms, improve functional capacity and quality of life, and reduce morbidity, mortality and hospitalisation. Here, the available treatments and key clinical trials are discussed


Naushad Hirani MD FRCPC Jason Weatherald MD FRCPC Division of Respiratory Medicine, University of Calgary, Canada


The main goals of pulmonary arterial hypertension (PAH) treatment are to alleviate symptoms, improve functional capacity and quality of life, and reduce morbidity, mortality and hospitalisation. General measures, such as psychosocial support and immunisation, rehabilitation/exercise, supportive treatment with anticoagulants, diuretics, digitalis and oxygen, are important, but are not sufficient to treat patients presenting with symptomatic PAH. Agents targeting the endothelin-1 (ET-1), nitric oxide (NO) and prostacyclin (PGI2) pathways, known to play important roles in the pathophysiology of the disease, are the mainstay in management of patients with idiopathic non-vasoreactive PAH.1


Patients with acutely vasoreactive PAH must be distinguished from


nonvasoreactive patients with right heart catheterisation. High-dose calcium channel blockers (CCBs) are reserved for these patients who clearly have a distinct pathobiology and prognosis, as CCBs can be dangerous in the majority of PAH patients with a fixed pulmonary vascular resistance.


Mechanisms of action


ET-1 is a vasoconstrictor and mitogenic peptide that binds to endothelin-A receptors (ETA), present in the vascular smooth muscle cells of the lung, and to endothelin-B receptors (ETB), also located in endothelial cells. The


deleterious effects of ET-1 signalling, namely fibrosis and hypertrophy of blood vessels, are thought to be mitigated with endothelin receptor antagonists (ERAs). NO induces vasodilation and inhibits proliferation of smooth muscle cells by increasing production of cyclic guanosine monophosphate (cGMP) via activation of soluble guanylate cyclase (sGC). Patients with PAH seem to produce insufficient NO, which affects downstream synthesis of cGMP. Therefore, inhibition of phosphodiesterase type 5 (PDE-5), a currently used therapeutic strategy, leads to the accumulation of intracellular cGMP. sGC stimulation, on the other hand, promotes cGMP production and also constitutes a therapeutic approach


for attenuating the pathophysiologic effects observed in PAH. Similar to NO, PGI2 is a vasodilator whose expression is deficient in the endothelium in the lung of patients with PAH. A number of prostacyclin analogues are currently used to treat PAH and have been demonstrated to be very effective agents for this condition.2


ERAs


Ambrisentan, a non-sulfonamide ERA specific for ETA, is available in North America and the EU for the treatment of patients with World Health Organization (WHO) Group 1 PAH.3–5


The agent has


been evaluated as monotherapy in several randomised Phase III trials. In ARIES-1


www.hospitalpharmacyeurope.com 19


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44